Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur MARIA ANTONIETTA D'AGOSTINO

📍 Boulogne-Billancourt (92)HospitalierRPPS 10001552164
📊 Reconnaissance scientifique : 74/100📝 590 articles publiés📚 HAL (8)🎓 2 thèses dirigées

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

🎓 Diplômes

  • Diplôme éq d'un pays de l'EEE profession Médecin

📝 Autres formations

  • DEES Rhumatologie

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Thèses universitaires

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Direction de thèses

🎓 2 thèses dirigées

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

74

h articles cités ≥ h fois chacun. Un h de 74 = 74 publications avec 74+ citations.

Citations

19 610

Publications

590

i10-index

216

Thématiques principales

  • Rheumatoid Arthritis Research and Therapies ×287
  • Spondyloarthritis Studies and Treatments ×161
  • Autoimmune and Inflammatory Disorders Research ×76
  • Musculoskeletal synovial abnormalities and treatments ×69
  • Systemic Sclerosis and Related Diseases ×48
Voir sur OpenAlex ↗🆔 ORCID 0000-0002-5347-0060

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

  • GHU APHP UPS SITE AMBROISE PARE

    9 Avenue CHARLES DE GAULLE, 92104 Boulogne-Billancourt

    ☎ 0149095000Hospitalier

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Effects of different B-cell-depleting strategies on the lymphatic tissue

    Annals of the rheumatic diseases · 2025

    📚 17 citations🎯 RCR 6.22🔓 Open Access📄 PDF gratuit ↗
  • 2
    CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

    Nature medicine · 2026

    📚 8 citations🎯 RCR 8.00🩺 Clinique🔓 Open Access
    Lire l'abstract Crossref ↓

    Abstract Chimeric antigen receptor (CAR)-T cells are considered a powerful therapeutic tool to reset the immune system in patients with autoimmune diseases. Innovative trial designs are needed to allow feasible testing of the safety and efficacy of CAR-T cells in clinical studies. CASTLE (CAR-T cells in systemic B cell mediated autoimmune disease) is a phase 1/2a two-stage optimal design basket study that investigated the safety and efficacy of zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product, in patients with treatment-resistant systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM). The primary safety outcome was the rate of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The secondary clinical efficacy outcomes were remission of SLE according to DORIS criteria, no progression of interstitial lung disease in SSc and American College of Rheumatology (ACR) major/moderate response in IIM after 24 weeks. A total of 24 patients were enrolled (10 with SLE, 9 with SSc and 5 with IIM), all receiving a single infusion of Zorpo-cel after stopping immunosuppressive treatments and receiving standard lymphodepletion with cyclophosphamide and fludarabine. Primary and secondary endpoints of CASTLE were met. Regarding safety, no CRS higher than grade 2 and no ICANS occurred. Regarding efficacy, 22 of the 24 patients achieved predefined efficacy endpoints, with 9 out of 10 patients with SLE reaching DORIS remission, 9 out of 9 patients with SSc showing no disease progression, and 4 out of 5 patients with IIM reaching ACR major/moderate response. Furthermore, all patients remained free of glucocorticoids and any other immunosuppressive treatment over the entire observation period of 24 weeks. CASTLE suggests the feasibility, safety and efficacy of Zorpo-cel in three different autoimmune diseases and paves the way for conducting a pivotal study. ClinicalTrials.gov identifier: NCT06347718 , EudraCT identifier: 2022-001366-35 .

  • 3
    Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network

    Frontiers in pharmacology · 2025

    📚 6 citations🎯 RCR 2.58🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    BackgroundVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an adult-onset autoinflammatory condition resulting in severe, often treatment-refractory inflammation. Currently, there are no established treatment guidelines for VEXAS syndrome.ObjectivesTo assess the efficacy and safety of conventional disease-modifying antirheumatic drugs (cDMARDs) in a cohort of VEXAS patients.MethodsData from VEXAS patients were obtained from the International AIDA Network VEXAS registry.ResultsData from 36 VEXAS patients were evaluated, with 28 (77.8%) treated with cDMARDs as monotherapy - and concomitant glucocorticoids (GC) - and 8 (22.2%) receiving a combination of different cDMARDs plus GC. Complete response (CR), partial response (PR), and failure to cDMARDs monotherapy were reported in 4/22 (18.2%), 11/22 (50%), and 7/22 (31.8%) courses, respectively. All patients were treated with GCs at the start of cDMARD monotherapy, and no GC discontinuation was observed later. No significant differences were observed in the GC dosage from the start of cDMARDs to the 3-month (p = 0.43), 6-month (p = 0.31), and 12-month (p = 0.21) visits. Conversely, the GC sparing resulted to be statistically significant when using methotrexate (p = 0.02). As for cDMARDs combinations, no cases achieved CR, while PR was observed in 5/9 (55.6%). Seventeen adverse events were reported, seven of which led to discontinuation.ConclusionMany VEXAS patients report a partial benefit from cDMARDs, while a smaller yet not negligible number of patients exhibit a CR; cDMARDs remain a viable option for this disorder, especially when the initial GC dosage is low and the need for a steroid-sparing effect is not immediately urgent.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal23

▼

Lupus6

▼

Épidémiologie & registres4

▼

IA en rhumatologie3

▼

Revue / méta-analyse3

▼

Goutte2

▼

Pharmacovigilance2

▼

Revue générale2

▼

Anti-IL-231

▼

Arthrose1

▼

Biothérapies non-anti-TNF1

▼

Échographie1

▼

JAK inhibiteurs1

▼

Qualité de vie / PROMs1

▼

Recommandations1

▼

Rhumatisme psoriasique1

▼

Santé mentale / fatigue1

▼

Sclérodermie1

▼

Vascularites des gros vaisseaux1

▼

Vraie vie / RWE1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.